Targeting colon cancer with the novel STAT3 inhibitor bruceantinol

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Signal transducer and activator of transcription 3 (STAT3) is a key mediator in oncogenic signaling, constitutively active in approximately 70% of human cancers.
• The development of STAT3 inhibitors is crucial for cancer treatment, yet no approved inhibitors currently exist.

Purpose of the Study:

• To identify and characterize bruceantinol (BOL) as a novel STAT3 inhibitor.
• To evaluate the antitumor activity of BOL in human colorectal cancer (CRC) models.
• To investigate BOL's potential in combination therapy with MEK inhibitors.

Main Methods:

• In vitro and in vivo assays were used to assess BOL's inhibition of STAT3 DNA-binding and activation.
• Quantitative analysis of STAT3 target gene expression (MCL-1, PTTG1, survivin, c-Myc) was performed.
• Structure-activity relationship studies were conducted to understand BOL's interaction with STAT3.
• Combination therapy studies with MEK inhibitors were evaluated in CRC models.

Main Results:

• BOL demonstrated potent inhibition of STAT3 DNA-binding (IC50 = 2.4 pM) and blocked STAT3 activation in a dose- and time-dependent manner.
• BOL suppressed the transcription of STAT3 target genes involved in anti-apoptosis and cell-cycle regulation.
• BOL significantly inhibited CRC tumor xenografts in vivo, with efficacy dependent on STAT3 presence.
• BOL sensitized tumors to MEK inhibitors by repressing p-STAT3 and MCL-1 induction.

Conclusions:

• Bruceantinol (BOL) is a novel STAT3 inhibitor with significant antitumor activity in colorectal cancer.
• BOL can be a valuable therapeutic agent for CRC, used alone or in combination with MEK inhibitors.